The tumor-draining lymph node as an immune-privileged site.
about
Central role of defective interleukin-2 production in the triggering of islet autoimmune destructionEngineering opportunities in cancer immunotherapyTechnical Considerations for the Generation of Adoptively Transferred T Cells in Cancer ImmunotherapyDendritic cell-based vaccine efficacy: aiming for hot spotsIn vivo imaging of T cell delivery to tumors after adoptive transfer therapy.A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.Towards a genetic definition of cancer-associated inflammation: role of the IDO pathwayKit (W-sh) mice develop earlier and more severe experimental autoimmune encephalomyelitis due to absence of immune suppression.Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotionChronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase.T cell subpopulations in lymph nodes may not be predictive of patient outcome in colorectal cancerCancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenaseAltered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases.Lymphangiogenesis in breast cancer is associated with non-sentinel lymph node metastases in sentinel node positive patients.Increasing the efficacy of tumor cell vaccines by enhancing cross primingRole of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice.TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma.Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma modelOX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection.Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment areaLocal delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.Indoleamine 2,3-dioxygenase and tumor-induced toleranceTumor-associated antigens and biomarkers in cancer and immune therapy.Apoptotic tumor cells induce IL-27 release from human DCs to activate Treg cells that express CD69 and attenuate cytotoxicity.Advancements in immune toleranceSignaling defects in anti-tumor T cellsRecombinant lentivector as a genetic immunization vehicle for antitumor immunity.Tissue destruction caused by cytotoxic T lymphocytes induces deletional tolerance.Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?Tumor regulatory T cells potently abrogate antitumor immunity.The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase.Mast cells as regulators of adaptive immunity to tumours.Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.In situ analysis of FOXP3(+) regulatory T cells and myeloid dendritic cells in human colorectal cancer tissue and tumor-draining lymph node.Local targets for immune therapy to cancer: tumor draining lymph nodes and tumor microenvironment.Engineering approaches to immunotherapy.Various ways to improve whole cancer cell vaccines.
P2860
Q24650734-5A1EA9DD-6824-4B39-AFAE-A3E68FE8E4A5Q26776373-2193CBB1-FFEA-48E1-882B-26EB4A09873DQ28073563-09910BAF-AF4A-4B9B-B51F-91A692F010ECQ28082680-F9D56642-A05A-49EE-BDA0-F8A513123E8AQ30479855-942CF214-A7E4-42A3-9502-070B787868AAQ33671350-0363F321-B28B-4EF4-B240-33B4AD2FA2E2Q33816244-A26B03C6-9859-4A3F-B2D0-592578E19772Q34359908-A03912F0-21CF-47E4-9B8E-6516391BF08FQ34393455-8AA73BDF-B2A5-4ECB-B0BE-2D54191A622CQ34657500-09CB7DE4-35E1-4994-9D7F-6FD181568CDEQ35232006-E698B9A8-533F-445F-9281-DE46F44BFB29Q35439417-A9F7192A-FF38-4481-9B13-7C22A015F231Q35925641-1984D0B1-F271-4A48-8FC0-8581E71C7B3BQ35952614-8E4AAF2B-3531-4F25-A55D-835A391D8B0BQ36261683-73DD9054-109C-4999-A0AF-49B46D43D1A3Q36288105-77F80AAE-37F8-4E88-A61F-80177ABE4C9AQ36303643-0303BEA0-C8CD-4DB5-A0F9-D80BE9C09BA1Q36343879-F1B9326E-1B15-4564-AE3B-7594F400D96FQ36514324-B4D87B14-497D-4CB1-A104-B0D0BBDDC49BQ36537926-408C1CD3-3DE2-4B38-9941-BB0AC6C0B4F7Q36544888-DED9F902-F1E3-4EDB-B080-553E4782F757Q36783070-09786C8D-C7B6-4620-BAAA-10FC69A25ACFQ36809762-0B000CA2-046C-4EF0-910D-51F72BB7EC46Q36844959-F3DCC580-B6CC-4D79-8316-62A7E75722DFQ36922033-3F374520-B4D3-4475-A2BA-CD67B6D8596FQ36988746-376E8294-1F22-47E0-8BC7-DAF4E1727D9EQ37063739-538E9071-47CE-48EF-ABDF-93DEFD3C3B10Q37123441-F484CED5-6D5C-47D1-9EBD-A9A8C7D82F2FQ37129429-C1B456DB-CC56-49B1-8C5F-868D46E2A092Q37234611-ABF642EE-4AD7-4463-A5CC-5C2687A4E68DQ37302327-D238E407-D2D3-42A3-98DB-D43F2DD00574Q37317190-40D17381-ABD4-4354-9641-5A016AC202F1Q37329058-3A984917-FB50-47A8-AE28-4B5A68EB1FA9Q37334065-8C973E35-0259-47B5-9669-0D5723436AA2Q37348856-9BC33876-71C0-4119-92B0-64A02199540DQ37522460-C5619314-4115-4983-8B7C-8F79FF18B5BDQ37640999-53D19A66-2482-4F35-B243-ED705557C4F7Q38031760-BA555232-8E84-4EED-8F8D-47BBE9134235Q38036894-CD22AD26-7D4B-4E85-A5AF-9BD7A7ECA3D9Q38206582-FF3ABF88-7E11-475D-B09F-12E2D34E465C
P2860
The tumor-draining lymph node as an immune-privileged site.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
The tumor-draining lymph node as an immune-privileged site.
@ast
The tumor-draining lymph node as an immune-privileged site.
@en
type
label
The tumor-draining lymph node as an immune-privileged site.
@ast
The tumor-draining lymph node as an immune-privileged site.
@en
prefLabel
The tumor-draining lymph node as an immune-privileged site.
@ast
The tumor-draining lymph node as an immune-privileged site.
@en
P2860
P1476
The tumor-draining lymph node as an immune-privileged site.
@en
P2093
Andrew L Mellor
David H Munn
P2860
P304
P356
10.1111/J.1600-065X.2006.00444.X
P577
2006-10-01T00:00:00Z